Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating on May 19.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Buy rating due to a combination of factors that highlight the promising potential of Tectonic Therapeutic’s TX45. The Phase 1b trial results presented at the ESC Heart Failure Congress demonstrated significant hemodynamic benefits from a single intravenous infusion of TX45. In particular, the treatment showed a notable reduction in pulmonary vascular resistance and pulmonary capillary wedge pressure, indicating its efficacy in improving heart function in patients with PH-HFpEF.
Additionally, the echocardiographic data revealed sustained improvements in right heart function, with key measures of heart performance showing consistent enhancement over a 29-day period. Importantly, the safety profile of TX45 was favorable, with no serious adverse events reported, suggesting a well-tolerated treatment. These positive outcomes, along with the ongoing Phase 2 APEX trial and the potential market expansion, underpin Risinger’s optimistic outlook and the Buy rating on TECX shares.
In another report released on May 19, Mizuho Securities also reiterated a Buy rating on the stock with a $85.00 price target.